score_bin	sensitive_predictive_implication	resistance_predictive_implication	prognostic_predictive_implication	feature_type	feature	alteration_type	alteration	tumor_f	total_coverage	exac_af	exac_common	clinvar	sensitive_score_bin	sensitive_therapy_name	sensitive_therapy_strategy	sensitive_therapy_type	sensitive_description	sensitive_citation	sensitive_url	resistance_score_bin	resistance_therapy_name	resistance_therapy_strategy	resistance_therapy_type	resistance_description	resistance_citation	resistance_url	prognostic_score_bin	favorable_prognosis	prognostic_description	prognostic_citation	prognostic_url	number_germline_mutations_in_gene	validation_total_coverage	validation_tumor_f	validation_detection_power	feature_display	preclinical_efficacy_observed	patient_id	tumor_sample_barcode	normal_sample_barcode
Putatively Actionable	Clinical evidence		Guideline	Somatic Variant	NRAS	Missense	p.Q61R	0.4457	341.0	0.0	0.0		Putatively Actionable	Selumetinib	MEK inhibition	Targeted therapy	Presence of this variant may suggest sensitivity to Selumetinib.	Adjei AA, Cohen RB, Franklin W, et al. Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J Clin Oncol. 2008;26(13):2139-46.	https://doi.org/10.1200/JCO.2007.14.4956								Investigate Actionability	0.0	More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	0	0.0	0.0	0.0	NRAS p.Q61R (Missense)	1.0	MEL-IPI_Pat28	MEL-IPI_Pat28-Tumor-SM-4DK1O	MEL-IPI_Pat28-Normal-SM-4NFUU
Putatively Actionable	Preclinical			Copy Number	CDKN2A	Deletion				0.0	0.0		Putatively Actionable	EPZ015666	PRMT5 inhibition	Targeted therapy	These deletions are typically codeleted with MTAP, which has enhanced dependency on PRMT5 for which there is an inhibitor in clincial development	Kryukov GV, Wilson FH, Ruth JR, et al. MTAP deletion confers enhanced dependency on the PRMT5 arginine methyltransferase in cancer cells. Science. 2016;351(6278):1214-8.	https://doi.org/10.1126/science.aad5214													0				CDKN2A Deletion		MEL-IPI_Pat28	MEL-IPI_Pat28-Tumor-SM-4DK1O	
Investigate Actionability	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.S467L	0.4118	187.0	0.0	0.0		Investigate Actionability	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Investigate Actionability	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Investigate Actionability	0.0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	0	0.0	0.0	0.0	BRAF p.S467L (Missense)	1.0	MEL-IPI_Pat28	MEL-IPI_Pat28-Tumor-SM-4DK1O	MEL-IPI_Pat28-Normal-SM-4NFUU
Investigate Actionability	FDA-Approved	Guideline		Somatic Variant	EGFR	Missense	p.E27K	0.1714	35.0	0.0	0.0		Investigate Actionability	Osimertinib	EGFR inhibition	Targeted therapy	Osimertinib is a kinase inhibitor indicated for the treatment of patients with metastatic epidermal growth factor receptor (EGFR) T790M mutation positive non-small cell lung cancer (NSCLC), as detected by an FDAapproved test, whose disease has progressed on or after EGFR TKI therapy.	AstraZeneca Pharmaceuticals, LP. Tagrisso (osimertinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208065s016lbl.pdf. Revised May 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208065s016lbl.pdf	Investigate Actionability	Gefitinib	EGFR inhibition	Targeted therapy	Second-site mutations within the EGFR kinase domain, such as T790M, are associated with acquired resistance to EGFR TKIs.	National Comprehensive Cancer Network. Non-Small Cell Lung Cancer NCCN Evidence Blocks (Version 1.2017). Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/nscl_blocks.pdf						0	0.0	0.0	0.0	EGFR p.E27K (Missense)	1.0	MEL-IPI_Pat28	MEL-IPI_Pat28-Tumor-SM-4DK1O	MEL-IPI_Pat28-Normal-SM-4NFUU
Investigate Actionability	FDA-Approved		Guideline	Somatic Variant	EZH2	Missense	p.E197K	0.0478	230.0	0.0	0.0		Investigate Actionability	Tazemetostat	EZH2 inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted accelerated approval to tazemetostat, an EZH2 inhibitor, for adult patients with relapsed or refactory (R/R) follicular lymphoma (FL) whose tumors are positive for an EZH2 mutation as detected by an FDA-approved test and who have received at least 2 prior systemic therapies, and for adult patients with R/R FL who have no satisfactory alternative treatment options.	Epizyme, Inc. Tazverik (tazemetostat) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213400s000lbl.pdf. Revised June 2020. Accessed November 4th, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213400s000lbl.pdf								Investigate Actionability	0.0	Most frequent in Chronic Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	0	0.0	0.0	0.0	EZH2 p.E197K (Missense)		MEL-IPI_Pat28	MEL-IPI_Pat28-Tumor-SM-4DK1O	MEL-IPI_Pat28-Normal-SM-4NFUU
Investigate Actionability	Clinical evidence	Clinical evidence		Somatic Variant	RET	Missense	p.P996L	0.6029	204.0	0.0	0.0		Investigate Actionability	LOXO-292	RET inhibition	Targeted therapy	Certain missesnse mutations may predict sensitivity to RET inhibitors	Subbiah V, Velcheti V, Tuch BB, et al. Selective RET kinase inhibition for patients with RET-altered cancers. Ann Oncol. 2018;29(8):1869-1876.	https://doi.org/10.1093/annonc/mdy137	Investigate Actionability	LOXO-292	RET inhibition	Targeted therapy	Certain missesnse mutations may predict resistance to RET inhibitors	Subbiah V, Velcheti V, Tuch BB, et al. Selective RET kinase inhibition for patients with RET-altered cancers. Ann Oncol. 2018;29(8):1869-1876.	https://doi.org/10.1093/annonc/mdy137						0	0.0	0.0	0.0	RET p.P996L (Missense)		MEL-IPI_Pat28	MEL-IPI_Pat28-Tumor-SM-4DK1O	MEL-IPI_Pat28-Normal-SM-4NFUU
Investigate Actionability	Clinical evidence			Somatic Variant	TSC2	Nonsense	p.W896*	0.1897	195.0	0.0	0.0		Investigate Actionability	Everolimus	PI3K/AKT/mTOR inhibition	Targeted therapy	Loss of function mutations in TSC1, TSC2, or FLCN may predict sensitivity to mTOR inhibition	Iyer G, Hanrahan AJ, Milowsky MI, et al. Genome sequencing identifies a basis for everolimus sensitivity. Science. 2012;338(6104):221.	https://doi.org/10.1126/science.1226344													0	0.0	0.0	0.0	TSC2 p.W896* (Nonsense)		MEL-IPI_Pat28	MEL-IPI_Pat28-Tumor-SM-4DK1O	MEL-IPI_Pat28-Normal-SM-4NFUU
Investigate Actionability	Clinical evidence			Somatic Variant	ERCC2	Missense	p.G607R	0.5414	133.0	0.0	0.0		Investigate Actionability	Cisplatin	Platinum-based chemotherapy	Chemotherapy	Somatic mutations that occured in ERCC2 were enriched in responders relative to nonresponsers in a cohort of patients with muscle-invasive urothelial carcinoma who received neoadjuvant cisplatin-based chemotherapy followed by cystectomy.	Liu D, Plimack ER, Hoffman-censits J, et al. Clinical Validation of Chemotherapy Response Biomarker ERCC2 in Muscle-Invasive Urothelial Bladder Carcinoma. JAMA Oncol. 2016;2(8):1094-6.	https://doi.org/10.1001/jamaoncol.2016.1056													0	0.0	0.0	0.0	ERCC2 p.G607R (Missense)	0.0	MEL-IPI_Pat28	MEL-IPI_Pat28-Tumor-SM-4DK1O	MEL-IPI_Pat28-Normal-SM-4NFUU
Investigate Actionability	Clinical evidence			Somatic Variant	ERCC2	Missense	p.L397F	0.2178	101.0	0.0	0.0		Investigate Actionability	Cisplatin	Platinum-based chemotherapy	Chemotherapy	Somatic mutations that occured in ERCC2 were enriched in responders relative to nonresponsers in a cohort of patients with muscle-invasive urothelial carcinoma who received neoadjuvant cisplatin-based chemotherapy followed by cystectomy.	Liu D, Plimack ER, Hoffman-censits J, et al. Clinical Validation of Chemotherapy Response Biomarker ERCC2 in Muscle-Invasive Urothelial Bladder Carcinoma. JAMA Oncol. 2016;2(8):1094-6.	https://doi.org/10.1001/jamaoncol.2016.1056													0	0.0	0.0	0.0	ERCC2 p.L397F (Missense)	0.0	MEL-IPI_Pat28	MEL-IPI_Pat28-Tumor-SM-4DK1O	MEL-IPI_Pat28-Normal-SM-4NFUU
Investigate Actionability	Clinical evidence			Mutational Burden	High Mutational Burden								Investigate Actionability	Ipilimumab	CTLA-4 inhibition	Immunotherapy	In a study of malignant melanoma using a discovery cohort of 25 patients and a validation cohort of 39 patients, a significantly higher muational burden was seen in patients with a long-term clinical benefit vs. patients with minimal or no benefit to ipilimumab treatment.	Snyder A, Makarov V, Merghoub T, et al. Genetic basis for clinical response to CTLA-4 blockade in melanoma. N Engl J Med. 2014;371(23):2189-99.	https://doi.org/10.1056/NEJMoa1406498													0				 mutations per Mb		MEL-IPI_Pat28		
Investigate Actionability	Preclinical	Preclinical		Somatic Variant	ALK	Missense	p.S295F	0.2963	162.0	2.5e-05	0.0		Investigate Actionability	Ceritinib	ALK inhibition	Targeted therapy	Ceritinib (LDK378), an ALK TKI, was evaluated in the context of crizotinib resistant ALK rearrangement positive non-small cell lung cancers. It was found that Certinib potently overcame crizotinib-resistant mutations. In particular, L1196M, G1269A, I1171T, S1206Y but it was not able to overcome G1202R and F1174C.	Friboulet L, Li N, Katayama R, et al. The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer. Cancer Discov. 2014;4(6):662-673.	https://doi.org/10.1158/2159-8290.CD-13-0846	Investigate Actionability	Ceritinib	ALK inhibition	Targeted therapy	Ceritinib (LDK378), an ALK TKI, was evaluated in the context of crizotinib resistant ALK rearrangement positive non-small cell lung cancers. It was found that Certinib potently overcame crizotinib-resistant mutations. In particular, L1196M, G1269A, I1171T, S1206Y but it was not able to overcome G1202R and F1174C.	Friboulet L, Li N, Katayama R, et al. The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer. Cancer Discov. 2014;4(6):662-673.	https://doi.org/10.1158/2159-8290.CD-13-0846						0	0.0	0.0	0.0	ALK p.S295F (Missense)		MEL-IPI_Pat28	MEL-IPI_Pat28-Tumor-SM-4DK1O	MEL-IPI_Pat28-Normal-SM-4NFUU
Investigate Actionability	Preclinical		Clinical trial	Somatic Variant	PIK3CA	Missense	p.P449L	0.1063	254.0	0.0	0.0		Investigate Actionability	Pictilisib	PI3K/AKT/mTOR inhibition	Targeted therapy	In vivo models harboring PIK3CA variants were especially sensitive to GDC-0941.	O'Brien C, Wallin JJ, Sampath D, et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res. 2010;16(14):3670-83.	https://doi.org/10.1158/1078-0432.CCR-09-2828								Investigate Actionability	0.0	Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status.	Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999.	https://doi.org/10.1200/JCO.2017.75.7310	0	0.0	0.0	0.0	PIK3CA p.P449L (Missense)	1.0	MEL-IPI_Pat28	MEL-IPI_Pat28-Tumor-SM-4DK1O	MEL-IPI_Pat28-Normal-SM-4NFUU
Investigate Actionability	Preclinical		Clinical trial	Somatic Variant	PIK3CA	Missense	p.A995V	0.05	220.0	0.0	0.0		Investigate Actionability	Pictilisib	PI3K/AKT/mTOR inhibition	Targeted therapy	In vivo models harboring PIK3CA variants were especially sensitive to GDC-0941.	O'Brien C, Wallin JJ, Sampath D, et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res. 2010;16(14):3670-83.	https://doi.org/10.1158/1078-0432.CCR-09-2828								Investigate Actionability	0.0	Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status.	Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999.	https://doi.org/10.1200/JCO.2017.75.7310	0	53.0	0.0377	0.3252	PIK3CA p.A995V (Missense)	1.0	MEL-IPI_Pat28	MEL-IPI_Pat28-Tumor-SM-4DK1O	MEL-IPI_Pat28-Normal-SM-4NFUU
Investigate Actionability	Preclinical		Clinical evidence	Somatic Variant	JAK1	Missense	p.E37K	0.2673	202.0	0.0	0.0		Investigate Actionability	PU-H71	HSP90 inhibition	Targeted therapy	MOHITO JAK1 V658F transplated mice were highly sensitive to growth inhibition by PU-H71.	Kucine N, Marubayashi S, Bhagwat N, et al. Tumor-specific HSP90 inhibition as a therapeutic approach in JAK-mutant acute lymphoblastic leukemias. Blood. 2015;126(22):2479-83.	https://doi.org/10.1182/blood-2015-03-635821								Investigate Actionability	0.0	A study of target-specific sequencing data taken from 112 ALL patients showed an association between JAK1 or JAK2 mutation and decreased survival.	Feng J, Li Y, Jia Y, et al. Spectrum of somatic mutations detected by targeted next-generation sequencing and their prognostic significance in adult patients with acute lymphoblastic leukemia. J Hematol Oncol. 2017;10(1):61.	https://doi.org/10.1186/s13045-017-0431-1	0	0.0	0.0	0.0	JAK1 p.E37K (Missense)		MEL-IPI_Pat28	MEL-IPI_Pat28-Tumor-SM-4DK1O	MEL-IPI_Pat28-Normal-SM-4NFUU
Investigate Actionability	Preclinical		Clinical evidence	Somatic Variant	JAK1	Missense	p.A17V	0.2107	242.0	0.0	0.0		Investigate Actionability	PU-H71	HSP90 inhibition	Targeted therapy	MOHITO JAK1 V658F transplated mice were highly sensitive to growth inhibition by PU-H71.	Kucine N, Marubayashi S, Bhagwat N, et al. Tumor-specific HSP90 inhibition as a therapeutic approach in JAK-mutant acute lymphoblastic leukemias. Blood. 2015;126(22):2479-83.	https://doi.org/10.1182/blood-2015-03-635821								Investigate Actionability	0.0	A study of target-specific sequencing data taken from 112 ALL patients showed an association between JAK1 or JAK2 mutation and decreased survival.	Feng J, Li Y, Jia Y, et al. Spectrum of somatic mutations detected by targeted next-generation sequencing and their prognostic significance in adult patients with acute lymphoblastic leukemia. J Hematol Oncol. 2017;10(1):61.	https://doi.org/10.1186/s13045-017-0431-1	0	0.0	0.0	0.0	JAK1 p.A17V (Missense)		MEL-IPI_Pat28	MEL-IPI_Pat28-Tumor-SM-4DK1O	MEL-IPI_Pat28-Normal-SM-4NFUU
Investigate Actionability	Preclinical			Somatic Variant	FBXW7	Missense	p.R505C	0.4253	221.0	0.0	0.0		Investigate Actionability	Sirolimus	PI3K/AKT/mTOR inhibition	Targeted therapy	Breast cancer tumor cell lines harboring deletions or mutations in FBXW7 are particularly sensitive to rapamycin treatment, FBXW7 may be a biomarker for human cancers susceptible to treatment with inhibitors of the mTOR pathway.	Mao JH, Kim IJ, Wu D, et al. FBXW7 targets mTOR for degradation and cooperates with PTEN in tumor suppression. Science. 2008;321(5895):1499-502.	https://doi.org/10.1126/science.1162981													0	0.0	0.0	0.0	FBXW7 p.R505C (Missense)		MEL-IPI_Pat28	MEL-IPI_Pat28-Tumor-SM-4DK1O	MEL-IPI_Pat28-Normal-SM-4NFUU
Investigate Actionability	Preclinical			Somatic Variant	SMARCA4	Nonsense	p.Q1071*	0.163	135.0	0.0	0.0		Investigate Actionability	VX-680	Aurora kinase inhibition	Targeted therapy	SMARCA4 inactivating mutations and sensitivity to AURKA inhibitor in preclinical models of non small cell lung adenocarcinoma	Tagal V, Wei S, Zhang W, et al. SMARCA4-inactivating mutations increase sensitivity to Aurora kinase A inhibitor VX-680 in non-small cell lung cancers. Nat Commun. 2017;8:14098.	https://doi.org/10.1038/ncomms14098													0	758.0	0.0607	1.0	SMARCA4 p.Q1071* (Nonsense)		MEL-IPI_Pat28	MEL-IPI_Pat28-Tumor-SM-4DK1O	MEL-IPI_Pat28-Normal-SM-4NFUU
Investigate Actionability	Preclinical			Somatic Variant	SMARCA4	Splice Site		0.0619	388.0	0.0	0.0		Investigate Actionability	VX-680	Aurora kinase inhibition	Targeted therapy	SMARCA4 inactivating mutations and sensitivity to AURKA inhibitor in preclinical models of non small cell lung adenocarcinoma	Tagal V, Wei S, Zhang W, et al. SMARCA4-inactivating mutations increase sensitivity to Aurora kinase A inhibitor VX-680 in non-small cell lung cancers. Nat Commun. 2017;8:14098.	https://doi.org/10.1038/ncomms14098													0	0.0	0.0	0.0	SMARCA4  (Splice Site)		MEL-IPI_Pat28	MEL-IPI_Pat28-Tumor-SM-4DK1O	MEL-IPI_Pat28-Normal-SM-4NFUU
Investigate Actionability		Clinical evidence		Somatic Variant	AR	Missense	p.L806P	0.7089	79.0	0.0	0.0									Investigate Actionability	Abiraterone	Antiandrogen	Hormone therapy	Androgen receptor mutation may predict resistance to second generation androgen deprivation or direct androgen inhibitors.	Chen EJ, Sowalsky AG, Gao S, et al. Abiraterone treatment in castration-resistant prostate cancer selects for progesterone responsive mutant androgen receptors. Clin Cancer Res. 2015;21(6):1273-80.	https://doi.org/10.1158/1078-0432.CCR-14-1220						0	0.0	0.0	0.0	AR p.L806P (Missense)		MEL-IPI_Pat28	MEL-IPI_Pat28-Tumor-SM-4DK1O	MEL-IPI_Pat28-Normal-SM-4NFUU
Investigate Actionability			Guideline	Somatic Variant	SETBP1	Missense	p.A1023V	0.2039	152.0	0.0	0.0																Investigate Actionability	0.0	Associated with disease progression. More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	0	0.0	0.0	0.0	SETBP1 p.A1023V (Missense)		MEL-IPI_Pat28	MEL-IPI_Pat28-Tumor-SM-4DK1O	MEL-IPI_Pat28-Normal-SM-4NFUU
Investigate Actionability			Clinical evidence	Somatic Variant	JAK2	Missense	p.P197S	0.2443	131.0	0.0	0.0																Investigate Actionability	0.0	In a retrospective study of 244 patients, significantly more patients with a JAK2 V617F variant than without had complications (secondary fibrosis, hemorrhage, and thrombosis) and had received cytoreductive treatment.	Kralovics R, Passamonti F, Buser AS, et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med. 2005;352(17):1779-90.	https://doi.org/10.1056/NEJMoa051113	0	0.0	0.0	0.0	JAK2 p.P197S (Missense)		MEL-IPI_Pat28	MEL-IPI_Pat28-Tumor-SM-4DK1O	MEL-IPI_Pat28-Normal-SM-4NFUU
Investigate Actionability			Clinical evidence	Somatic Variant	BCOR	Missense	p.S91F	0.0842	95.0	0.0	0.0																Investigate Actionability	0.0	More frequent in Chronic Myelomonocytic Leukemia.	O'Brien C, Wallin JJ, Sampath D, et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res. 2010;16(14):3670-83.	https://doi.org/10.1158/1078-0432.CCR-09-2828	0	53.0	0.1321	0.6771	BCOR p.S91F (Missense)		MEL-IPI_Pat28	MEL-IPI_Pat28-Tumor-SM-4DK1O	MEL-IPI_Pat28-Normal-SM-4NFUU
Investigate Actionability			Inferential	Aneuploidy	Whole genome doubling																						Investigate Actionability	0.0	WGD was associated with adverse survival pan-cancer in patients with advanced disease and in cancers with heterogeneous clinical outcomes, even following the development of metastasis.	Bielski CM, Zehir A, Penson AV, et al. Genome doubling shapes the evolution and prognosis of advanced cancers Nat Genet. 2018; 50(8):1189-1195.	https://doi.org/10.1038/s41588-018-0165-1	0						MEL-IPI_Pat28		
Investigate Actionability	FDA-Approved	Clinical evidence		Somatic Variant	BRCA1	Missense	p.S646N	0.0469	213.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval for olaparib for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA-mutated advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy. 	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s018lbl.pdf. Revised November 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s018lbl.pdf	Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	Secondary mutations in BRCA1 may confer resistance to PARP inhibition in ovarian cancer	Lheureux S, Bruce JP, Burnier JV, et al. Somatic BRCA1/2 Recovery as a Resistance Mechanism After Exceptional Response to Poly (ADP-ribose) Polymerase Inhibition. J Clin Oncol. 2017;:JCO2016713677.	https://doi.org/10.1200/JCO.2016.71.3677						0	81.0	0.0988	0.5660000000000001	BRCA1 p.S646N (Missense)	1.0	MEL-IPI_Pat28	MEL-IPI_Pat28-Tumor-SM-4DK1O	MEL-IPI_Pat28-Normal-SM-4NFUU
Investigate Actionability	FDA-Approved	Clinical evidence		Somatic Variant	BRCA1	Missense	p.A92V	0.0189	265.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval for olaparib for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA-mutated advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy. 	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s018lbl.pdf. Revised November 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s018lbl.pdf	Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	Secondary mutations in BRCA1 may confer resistance to PARP inhibition in ovarian cancer	Lheureux S, Bruce JP, Burnier JV, et al. Somatic BRCA1/2 Recovery as a Resistance Mechanism After Exceptional Response to Poly (ADP-ribose) Polymerase Inhibition. J Clin Oncol. 2017;:JCO2016713677.	https://doi.org/10.1200/JCO.2016.71.3677						0	121.0	0.0083	0.299	BRCA1 p.A92V (Missense)	1.0	MEL-IPI_Pat28	MEL-IPI_Pat28-Tumor-SM-4DK1O	MEL-IPI_Pat28-Normal-SM-4NFUU
Investigate Actionability	FDA-Approved			Somatic Variant	TSC1	Missense	p.E211K	0.0323	186.0	0.0	0.0		Investigate Actionability	Everolimus	PI3K/AKT/mTOR inhibition	Targeted therapy	Everolimus is indicated for the treatment of subependymal giant cell astrocytoma (SEGA) associated with tuberous sclerosis complex in adults and pediatric patients who are not candidates for curative surgical resection	Novartis Pharmaceuticals Corporation. Afinitor (everolimus) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/022334s044,203985s016lbl.pdf. Revised February 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/022334s044,203985s016lbl.pdf													0	106.0	0.0189	0.5199	TSC1 p.E211K (Missense)		MEL-IPI_Pat28	MEL-IPI_Pat28-Tumor-SM-4DK1O	MEL-IPI_Pat28-Normal-SM-4NFUU
Investigate Actionability	FDA-Approved			Somatic Variant	CDK12	Missense	p.P564S	0.2079	505.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf. Revised May 2020. Accessed 22 October, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf													0	0.0	0.0	0.0	CDK12 p.P564S (Missense)	0.0	MEL-IPI_Pat28	MEL-IPI_Pat28-Tumor-SM-4DK1O	MEL-IPI_Pat28-Normal-SM-4NFUU
Investigate Actionability	Guideline			Somatic Variant	TET2	Missense	p.S462N	0.1966	117.0	0.0	0.0		Investigate Actionability	Azacitidine	Hypomethylating agent chemotherapy	Chemotherapy	TET2 mutations are associated with an increased sensitivity to hypomethylating agents (such as AzaC). This increased sensitivity may be partially abrogated in the presence of ASXL1 mutations.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf													0	0.0	0.0	0.0	TET2 p.S462N (Missense)		MEL-IPI_Pat28	MEL-IPI_Pat28-Tumor-SM-4DK1O	MEL-IPI_Pat28-Normal-SM-4NFUU
Investigate Actionability	Guideline			Somatic Variant	TET2	Missense	p.L718F	0.2252	151.0	0.0	0.0		Investigate Actionability	Azacitidine	Hypomethylating agent chemotherapy	Chemotherapy	TET2 mutations are associated with an increased sensitivity to hypomethylating agents (such as AzaC). This increased sensitivity may be partially abrogated in the presence of ASXL1 mutations.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf													0	0.0	0.0	0.0	TET2 p.L718F (Missense)		MEL-IPI_Pat28	MEL-IPI_Pat28-Tumor-SM-4DK1O	MEL-IPI_Pat28-Normal-SM-4NFUU
Investigate Actionability	Clinical evidence	Clinical evidence		Somatic Variant	BRCA2	Missense	p.R113K	0.2584	89.0	0.0	0.0		Investigate Actionability	Nivolumab + Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	Responders were enriched for mutation in BRCA2 mutations, mostly nonsense mutations. 6 of 21 responders had BRCA2 vs. 1 of 17 nonresponders.	Hugo W, Zaretsky JM, Sun L, et al. Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma Cell. 2016; 165(1):35-44.	https://doi.org/10.1016/j.cell.2016.02.065	Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	Secondary mutations in BRCA2 may confer resistance to PARP inhibition in ovarian cancer	Lheureux S, Bruce JP, Burnier JV, et al. Somatic BRCA1/2 Recovery as a Resistance Mechanism After Exceptional Response to Poly (ADP-ribose) Polymerase Inhibition. J Clin Oncol. 2017;:JCO2016713677.	https://doi.org/10.1200/JCO.2016.71.3677						0	0.0	0.0	0.0	BRCA2 p.R113K (Missense)		MEL-IPI_Pat28	MEL-IPI_Pat28-Tumor-SM-4DK1O	MEL-IPI_Pat28-Normal-SM-4NFUU
Investigate Actionability	Clinical evidence	Clinical evidence		Somatic Variant	BRCA2	Missense	p.V1790I	0.24	100.0	0.0	0.0		Investigate Actionability	Nivolumab + Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	Responders were enriched for mutation in BRCA2 mutations, mostly nonsense mutations. 6 of 21 responders had BRCA2 vs. 1 of 17 nonresponders.	Hugo W, Zaretsky JM, Sun L, et al. Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma Cell. 2016; 165(1):35-44.	https://doi.org/10.1016/j.cell.2016.02.065	Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	Secondary mutations in BRCA2 may confer resistance to PARP inhibition in ovarian cancer	Lheureux S, Bruce JP, Burnier JV, et al. Somatic BRCA1/2 Recovery as a Resistance Mechanism After Exceptional Response to Poly (ADP-ribose) Polymerase Inhibition. J Clin Oncol. 2017;:JCO2016713677.	https://doi.org/10.1200/JCO.2016.71.3677						0	0.0	0.0	0.0	BRCA2 p.V1790I (Missense)		MEL-IPI_Pat28	MEL-IPI_Pat28-Tumor-SM-4DK1O	MEL-IPI_Pat28-Normal-SM-4NFUU
Investigate Actionability	Clinical evidence	Clinical evidence		Somatic Variant	BRCA2	Missense	p.S1871N	0.2584	89.0	4.1e-05	0.0		Investigate Actionability	Nivolumab + Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	Responders were enriched for mutation in BRCA2 mutations, mostly nonsense mutations. 6 of 21 responders had BRCA2 vs. 1 of 17 nonresponders.	Hugo W, Zaretsky JM, Sun L, et al. Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma Cell. 2016; 165(1):35-44.	https://doi.org/10.1016/j.cell.2016.02.065	Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	Secondary mutations in BRCA2 may confer resistance to PARP inhibition in ovarian cancer	Lheureux S, Bruce JP, Burnier JV, et al. Somatic BRCA1/2 Recovery as a Resistance Mechanism After Exceptional Response to Poly (ADP-ribose) Polymerase Inhibition. J Clin Oncol. 2017;:JCO2016713677.	https://doi.org/10.1200/JCO.2016.71.3677						0	0.0	0.0	0.0	BRCA2 p.S1871N (Missense)		MEL-IPI_Pat28	MEL-IPI_Pat28-Tumor-SM-4DK1O	MEL-IPI_Pat28-Normal-SM-4NFUU
Investigate Actionability	Clinical evidence	Clinical evidence		Somatic Variant	BRCA2	Missense	p.T3199I	0.0412	655.0	0.0	0.0		Investigate Actionability	Nivolumab + Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	Responders were enriched for mutation in BRCA2 mutations, mostly nonsense mutations. 6 of 21 responders had BRCA2 vs. 1 of 17 nonresponders.	Hugo W, Zaretsky JM, Sun L, et al. Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma Cell. 2016; 165(1):35-44.	https://doi.org/10.1016/j.cell.2016.02.065	Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	Secondary mutations in BRCA2 may confer resistance to PARP inhibition in ovarian cancer	Lheureux S, Bruce JP, Burnier JV, et al. Somatic BRCA1/2 Recovery as a Resistance Mechanism After Exceptional Response to Poly (ADP-ribose) Polymerase Inhibition. J Clin Oncol. 2017;:JCO2016713677.	https://doi.org/10.1200/JCO.2016.71.3677						0	0.0	0.0	0.0	BRCA2 p.T3199I (Missense)		MEL-IPI_Pat28	MEL-IPI_Pat28-Tumor-SM-4DK1O	MEL-IPI_Pat28-Normal-SM-4NFUU
Investigate Actionability	Clinical evidence			Somatic Variant	MSH2	Missense	p.G137D	0.0261	307.0	0.0	0.0		Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	Patients with defects in DNA mismatch repair genes may have enhanced sensitivity to immune checkpoint blockade.	Le DT, Uram JN, Wang H, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015;372(26):2509-20.	https://doi.org/10.1056/NEJMoa1500596													0	128.0	0.0	0.4894	MSH2 p.G137D (Missense)		MEL-IPI_Pat28	MEL-IPI_Pat28-Tumor-SM-4DK1O	MEL-IPI_Pat28-Normal-SM-4NFUU
Investigate Actionability	Clinical evidence			Somatic Variant	MSH6	Missense	p.S616F	0.2775	191.0	0.0	0.0		Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	Patients with defects in DNA mismatch repair genes may have enhanced sensitivity to immune checkpoint blockade.	Le DT, Uram JN, Wang H, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015;372(26):2509-20.	https://doi.org/10.1056/NEJMoa1500596													0	0.0	0.0	0.0	MSH6 p.S616F (Missense)		MEL-IPI_Pat28	MEL-IPI_Pat28-Tumor-SM-4DK1O	MEL-IPI_Pat28-Normal-SM-4NFUU
Investigate Actionability	Clinical evidence			Somatic Variant	MSH6	Missense	p.A794V	0.5652	161.0	0.0	0.0		Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	Patients with defects in DNA mismatch repair genes may have enhanced sensitivity to immune checkpoint blockade.	Le DT, Uram JN, Wang H, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015;372(26):2509-20.	https://doi.org/10.1056/NEJMoa1500596													0	0.0	0.0	0.0	MSH6 p.A794V (Missense)		MEL-IPI_Pat28	MEL-IPI_Pat28-Tumor-SM-4DK1O	MEL-IPI_Pat28-Normal-SM-4NFUU
Investigate Actionability	Clinical evidence			Somatic Variant	PBRM1	Missense	p.S1258F	0.1545	220.0	0.0	0.0		Investigate Actionability	Nivolumab	PD-1/PD-L1 inhibition	Immunotherapy	Clinical benefit from nivolumab in clear cell renal cell carcinoma patients was associated with loss-of-function mutations in PBRM1	Miao D, Margolis CA, Gao W, et al. Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma. Science. 2018;359(6377):801-806.	https://doi.org/10.1126/science.aan5951													0	0.0	0.0	0.0	PBRM1 p.S1258F (Missense)		MEL-IPI_Pat28	MEL-IPI_Pat28-Tumor-SM-4DK1O	MEL-IPI_Pat28-Normal-SM-4NFUU
Investigate Actionability	Clinical evidence			Somatic Variant	MLH3	Missense	p.M1006T	0.043	442.0	0.0	0.0		Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	Patients with defects in DNA mismatch repair genes may have enhanced sensitivity to immune checkpoint blockade.	Le DT, Uram JN, Wang H, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015;372(26):2509-20.	https://doi.org/10.1056/NEJMoa1500596													0	0.0	0.0	0.0	MLH3 p.M1006T (Missense)		MEL-IPI_Pat28	MEL-IPI_Pat28-Tumor-SM-4DK1O	MEL-IPI_Pat28-Normal-SM-4NFUU
Investigate Actionability	Clinical evidence			Somatic Variant	ERCC2	Nonsense	p.W696*	0.3182	154.0	2.5e-05	0.0		Investigate Actionability	Cisplatin	Platinum-based chemotherapy	Chemotherapy	Somatic mutations that occured in ERCC2 were enriched in responders relative to nonresponsers in a cohort of patients with muscle-invasive urothelial carcinoma who received neoadjuvant cisplatin-based chemotherapy followed by cystectomy.	Liu D, Plimack ER, Hoffman-censits J, et al. Clinical Validation of Chemotherapy Response Biomarker ERCC2 in Muscle-Invasive Urothelial Bladder Carcinoma. JAMA Oncol. 2016;2(8):1094-6.	https://doi.org/10.1001/jamaoncol.2016.1056													0	0.0	0.0	0.0	ERCC2 p.W696* (Nonsense)	0.0	MEL-IPI_Pat28	MEL-IPI_Pat28-Tumor-SM-4DK1O	MEL-IPI_Pat28-Normal-SM-4NFUU
Investigate Actionability			Guideline	Somatic Variant	PRPF8	Missense	p.E789K	0.0625	704.0	0.0	0.0																Investigate Actionability	0.0		National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	0	0.0	0.0	0.0	PRPF8 p.E789K (Missense)		MEL-IPI_Pat28	MEL-IPI_Pat28-Tumor-SM-4DK1O	MEL-IPI_Pat28-Normal-SM-4NFUU
Investigate Actionability			Guideline	Somatic Variant	ZRSR2	Missense	p.R452H	0.1091	55.0	1.7e-05	0.0																Investigate Actionability	0.0	NCCN guideline for Myelodysplastic Syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	0	11.0	0.0	0.0511	ZRSR2 p.R452H (Missense)		MEL-IPI_Pat28	MEL-IPI_Pat28-Tumor-SM-4DK1O	MEL-IPI_Pat28-Normal-SM-4NFUU
Investigate Actionability			Clinical evidence	Somatic Variant	BLM	Missense	p.P355S	0.0488	164.0	0.0	0.0																Investigate Actionability	0.0	BLM may indicate a predisposition for early onset of colorectal cancer, although with a low-moderate penetrance.	De voer RM, Hahn MM, Mensenkamp AR, et al. Deleterious Germline BLM Mutations and the Risk for Early-onset Colorectal Cancer. Sci Rep. 2015;5:14060.	https://doi.org/10.1038/srep14060	0	30.0	0.0	0.0928	BLM p.P355S (Missense)		MEL-IPI_Pat28	MEL-IPI_Pat28-Tumor-SM-4DK1O	MEL-IPI_Pat28-Normal-SM-4NFUU
Investigate Actionability			Clinical evidence	Somatic Variant	BLM	Missense	p.V524I	0.2314	121.0	0.0	0.0																Investigate Actionability	0.0	BLM may indicate a predisposition for early onset of colorectal cancer, although with a low-moderate penetrance.	De voer RM, Hahn MM, Mensenkamp AR, et al. Deleterious Germline BLM Mutations and the Risk for Early-onset Colorectal Cancer. Sci Rep. 2015;5:14060.	https://doi.org/10.1038/srep14060	0	0.0	0.0	0.0	BLM p.V524I (Missense)		MEL-IPI_Pat28	MEL-IPI_Pat28-Tumor-SM-4DK1O	MEL-IPI_Pat28-Normal-SM-4NFUU
Investigate Actionability			Clinical evidence	Somatic Variant	BLM	Splice Site	p.G1228E	0.1944	144.0	0.0	0.0																Investigate Actionability	0.0	BLM may indicate a predisposition for early onset of colorectal cancer, although with a low-moderate penetrance.	De voer RM, Hahn MM, Mensenkamp AR, et al. Deleterious Germline BLM Mutations and the Risk for Early-onset Colorectal Cancer. Sci Rep. 2015;5:14060.	https://doi.org/10.1038/srep14060	0	0.0	0.0	0.0	BLM p.G1228E (Splice Site)		MEL-IPI_Pat28	MEL-IPI_Pat28-Tumor-SM-4DK1O	MEL-IPI_Pat28-Normal-SM-4NFUU
Investigate Actionability			Clinical evidence	Somatic Variant	RBM10	Missense	p.G394D	0.0556	72.0	0.0	0.0																Investigate Actionability	1.0	RBM10 mutations were associated with better prognosis in a study of 109 microdissected pancreatic adenocarcinoma tumors. Note that all RBM10-mutant patients were found to have high-grade pT3 stage tumors.	Witkiewicz AK, Mcmillan EA, Balaji U, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun. 2015;6:6744.	https://doi.org/10.1038/ncomms7744	0	141.0	0.1277	0.9082	RBM10 p.G394D (Missense)		MEL-IPI_Pat28	MEL-IPI_Pat28-Tumor-SM-4DK1O	MEL-IPI_Pat28-Normal-SM-4NFUU
Biologically Relevant				Somatic Variant	MTOR	Missense	p.L2261F	0.2	35.0	0.0	0.0																					0	131.0	0.1832	0.9998	MTOR p.L2261F (Missense)		MEL-IPI_Pat28	MEL-IPI_Pat28-Tumor-SM-4DK1O	MEL-IPI_Pat28-Normal-SM-4NFUU
Biologically Relevant				Somatic Variant	TACC3	Missense	p.V169M	0.0546	183.0	0.0	0.0																					0	0.0	0.0	0.0	TACC3 p.V169M (Missense)		MEL-IPI_Pat28	MEL-IPI_Pat28-Tumor-SM-4DK1O	MEL-IPI_Pat28-Normal-SM-4NFUU
Biologically Relevant				Somatic Variant	TACC3	Missense	p.A686T	0.2434	189.0	0.0	0.0																					0	77.0	0.2208	1.0	TACC3 p.A686T (Missense)		MEL-IPI_Pat28	MEL-IPI_Pat28-Tumor-SM-4DK1O	MEL-IPI_Pat28-Normal-SM-4NFUU
Biologically Relevant				Somatic Variant	PDGFRB	Missense	p.T232I	0.0592	169.0	0.0	0.0																					0	28.0	0.0357	0.11699999999999999	PDGFRB p.T232I (Missense)		MEL-IPI_Pat28	MEL-IPI_Pat28-Tumor-SM-4DK1O	MEL-IPI_Pat28-Normal-SM-4NFUU
Biologically Relevant				Somatic Variant	CCND3	Missense	p.A230T	0.1102	127.0	0.0	0.0																					0	0.0	0.0	0.0	CCND3 p.A230T (Missense)		MEL-IPI_Pat28	MEL-IPI_Pat28-Tumor-SM-4DK1O	MEL-IPI_Pat28-Normal-SM-4NFUU
Biologically Relevant				Somatic Variant	ESRP1	Missense	p.E211K	0.2222	72.0	0.0	0.0																					0	0.0	0.0	0.0	ESRP1 p.E211K (Missense)		MEL-IPI_Pat28	MEL-IPI_Pat28-Tumor-SM-4DK1O	MEL-IPI_Pat28-Normal-SM-4NFUU
Biologically Relevant				Somatic Variant	CD274	Missense	p.G119S	0.0472	106.0	0.0	0.0																					0	44.0	0.0227	0.24600000000000002	CD274 p.G119S (Missense)		MEL-IPI_Pat28	MEL-IPI_Pat28-Tumor-SM-4DK1O	MEL-IPI_Pat28-Normal-SM-4NFUU
Biologically Relevant				Somatic Variant	FGFR2	Missense	p.V680A	0.0424	118.0	0.0	0.0																					0	0.0	0.0	0.0	FGFR2 p.V680A (Missense)		MEL-IPI_Pat28	MEL-IPI_Pat28-Tumor-SM-4DK1O	MEL-IPI_Pat28-Normal-SM-4NFUU
Biologically Relevant				Somatic Variant	RB1	Missense	p.D701N	0.0455	110.0	0.0	0.0																					0	198.0	0.0051	0.9424	RB1 p.D701N (Missense)		MEL-IPI_Pat28	MEL-IPI_Pat28-Tumor-SM-4DK1O	MEL-IPI_Pat28-Normal-SM-4NFUU
Biologically Relevant				Somatic Variant	NTRK3	Missense	p.V788I	0.2143	126.0	8e-06	0.0																					0	0.0	0.0	0.0	NTRK3 p.V788I (Missense)		MEL-IPI_Pat28	MEL-IPI_Pat28-Tumor-SM-4DK1O	MEL-IPI_Pat28-Normal-SM-4NFUU
Biologically Relevant				Somatic Variant	NF1	Missense	p.T737I	0.0271	258.0	0.0	0.0																					0	508.0	0.0059	0.9908	NF1 p.T737I (Missense)		MEL-IPI_Pat28	MEL-IPI_Pat28-Tumor-SM-4DK1O	MEL-IPI_Pat28-Normal-SM-4NFUU
Biologically Relevant				Somatic Variant	NF1	Missense	p.D1322N	0.0469	213.0	0.0	0.0																					0	0.0	0.0	0.0	NF1 p.D1322N (Missense)		MEL-IPI_Pat28	MEL-IPI_Pat28-Tumor-SM-4DK1O	MEL-IPI_Pat28-Normal-SM-4NFUU
Biologically Relevant				Somatic Variant	NF1	Splice Site		0.0292	342.0	0.0	0.0																					0	10.0	0.0	0.0003	NF1  (Splice Site)		MEL-IPI_Pat28	MEL-IPI_Pat28-Tumor-SM-4DK1O	MEL-IPI_Pat28-Normal-SM-4NFUU
Biologically Relevant				Somatic Variant	NF1	Missense	p.R1970K	0.2085	259.0	0.0	0.0																					0	0.0	0.0	0.0	NF1 p.R1970K (Missense)		MEL-IPI_Pat28	MEL-IPI_Pat28-Tumor-SM-4DK1O	MEL-IPI_Pat28-Normal-SM-4NFUU
Biologically Relevant				Somatic Variant	NF1	Missense	p.P2483L	0.1007	139.0	0.0	0.0																					0	0.0	0.0	0.0	NF1 p.P2483L (Missense)		MEL-IPI_Pat28	MEL-IPI_Pat28-Tumor-SM-4DK1O	MEL-IPI_Pat28-Normal-SM-4NFUU
Biologically Relevant				Somatic Variant	BRD4	Missense	p.P1170S	0.0847	189.0	0.0	0.0																					0	0.0	0.0	0.0	BRD4 p.P1170S (Missense)		MEL-IPI_Pat28	MEL-IPI_Pat28-Tumor-SM-4DK1O	MEL-IPI_Pat28-Normal-SM-4NFUU
Biologically Relevant				Somatic Variant	IL12RB1	Missense	p.P424S	0.2275	167.0	0.0	0.0																					0	0.0	0.0	0.0	IL12RB1 p.P424S (Missense)		MEL-IPI_Pat28	MEL-IPI_Pat28-Tumor-SM-4DK1O	MEL-IPI_Pat28-Normal-SM-4NFUU
Biologically Relevant				Somatic Variant	TPX2	Missense	p.G26R	0.1324	204.0	0.0	0.0																					0	0.0	0.0	0.0	TPX2 p.G26R (Missense)		MEL-IPI_Pat28	MEL-IPI_Pat28-Tumor-SM-4DK1O	MEL-IPI_Pat28-Normal-SM-4NFUU
Biologically Relevant				Somatic Variant	AURKA	Missense	p.G140D	0.1561	301.0	0.0	0.0																					0	0.0	0.0	0.0	AURKA p.G140D (Missense)		MEL-IPI_Pat28	MEL-IPI_Pat28-Tumor-SM-4DK1O	MEL-IPI_Pat28-Normal-SM-4NFUU
Biologically Relevant				Somatic Variant	ERG	Missense	p.E116K	0.1122	98.0	0.0	0.0																					0	0.0	0.0	0.0	ERG p.E116K (Missense)		MEL-IPI_Pat28	MEL-IPI_Pat28-Tumor-SM-4DK1O	MEL-IPI_Pat28-Normal-SM-4NFUU
Biologically Relevant				Somatic Variant	TMPRSS2	Missense	p.D174N	0.3385	130.0	0.0	0.0																					0	0.0	0.0	0.0	TMPRSS2 p.D174N (Missense)		MEL-IPI_Pat28	MEL-IPI_Pat28-Tumor-SM-4DK1O	MEL-IPI_Pat28-Normal-SM-4NFUU
Biologically Relevant				Somatic Variant	CRKL	Missense	p.P210S	0.2603	146.0	0.0	0.0																					0	0.0	0.0	0.0	CRKL p.P210S (Missense)		MEL-IPI_Pat28	MEL-IPI_Pat28-Tumor-SM-4DK1O	MEL-IPI_Pat28-Normal-SM-4NFUU
Biologically Relevant				Somatic Variant	EWSR1	Missense	p.T8I	0.2662	139.0	0.0	0.0																					0	0.0	0.0	0.0	EWSR1 p.T8I (Missense)		MEL-IPI_Pat28	MEL-IPI_Pat28-Tumor-SM-4DK1O	MEL-IPI_Pat28-Normal-SM-4NFUU
Biologically Relevant				Microsatellite Stability	Supporting variants		PRDM2 p.703_704insP (Insertion)																									0				Supporting variants: PRDM2 p.703_704insP (Insertion)		MEL-IPI_Pat28		
Biologically Relevant				Mutational Signature	COSMIC Signature 11	version 2	0.916																									0				COSMIC Signature (version 2) 11 (92%)		MEL-IPI_Pat28		
